Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions: Naproxen, Acetaminophen, oxycodone, Gabapentin; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteer
Interventions: danoprevir, darunavir, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: COVID-19
Interventions: ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose, Vehicle control; Drug · Other
Lead sponsor: Oryn Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Orange, California

Conditions: Heart Failure
Interventions: Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Beverly Hills, California • Lake Forest, California • Santa Maria, California + 18 more

Conditions: Healthy, Pharmacokinetics of ASP015K and Midazolam
Interventions: ASP015K, Midazolam; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obsessive - Compulsive Disorder
Interventions: Low Dose Psilocybin, High Dose Psilocybin; Drug
Lead sponsor: Francisco A Moreno; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Garetosmab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Nashville, Tennessee

Conditions: Epilepsy
Interventions: lacosamide, levetiracetam; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain
Interventions: Mindfulness, Naloxone, Saline, Meditation; Behavioral · Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Opioid Use, Spinal Diseases, Surgery--Complications, Surgery, Postoperative Pain
Interventions: Opioid Analgesic, Opioid-Free Postoperative Pain Regimen; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Aldesleukin, Peginterferon alfa-2b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation, FOLFIRINOX; Drug · Biological · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 76 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Liver Disease
Interventions: sofosbuvir/ledipasvir, sofosbuvir, Ribavirin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas

Conditions: Gingivitis
Interventions: 1X ACCS (Amnion-derived Cellular Cytokine Solution), Normal saline, 0.3X ACCS; Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Abuse, Alcohol Dependence
Interventions: Ondansetron, placebo ondansetron; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hot Flashes, Menopause, Vasomotor Disturbance
Interventions: Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 339 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Breast MRI
Interventions: Standard of care contrast agent, provided in split dose, Breast MRI; Drug · Diagnostic Test
Lead sponsor: Manojkumar Saranathan; Other
Eligibility: 30 Years to 89 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cystic Fibrosis
Interventions: IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more

Conditions: Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Interventions: IKS014; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: prednisone, methylprednisolone, questionnaire administration; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Substance Abuse Disorder
Interventions: Low intensity care, Voucher reinforcement; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more

Conditions: HIV Infections
Interventions: BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more

Conditions: Beta Thalassemia Intermedia, Sickle Cell Disease
Interventions: Benserazide Only Product; Drug
Lead sponsor: Phoenicia BioScience; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • Weston, Massachusetts + 1 more

Search by objective public record fields.

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

A Study to Assess Drug Interaction of ASP015K and Midazolam

Psilocybin for Treatment of OCD-2

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Add on Lacosamide Versus High Dose Monotherapy

Chronic Low Back Pain and Meditation

Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)

Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Low-dose Imaging TechniquE in Breast MRI

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

IKS014 in Advanced Solid Tumors That Express HER2

Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

The BENeFiTS Trial in Beta Thalassemia Intermedia